The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1274
Formoterol (Perforomist) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Formoterol fumarate (Perforomist – Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana), the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.1

MAINTENANCE TREATMENT OF COPD — For patients with moderate to severe disease, regular treatment with long-acting bronchodilators, which include long-acting beta2-agonists and the long-acting anticholinergic tiotropium, can relieve symptoms, increase exercise tolerance, improve lung function, reduce the frequency of exacerbations and improve quality of life.2 For patients with severe disease who experience frequent exacerbations, a trial of an added ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Formoterol (Perforomist) for COPD
Article code: 1274b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian